iBio, Inc. (IBIO)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $0.75
- As of
Kresmion compiles this page from IBIO's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
iBio, Inc. (IBIO): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q3 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-11-16.
See the full IBIO dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for IBIO on one page. Preview it with sample data, then open it live with a free account.
Preview the IBIO dossierActive events for IBIO
- high13F: large reduction
CITADEL ADVISORS LLC cut 52% of IBIO (2026Q3)
- high13F: large increase
RENAISSANCE TECHNOLOGIES LLC added +239% to IBIO (2026Q3)
- mediumEarnings above estimates
Q1-2027: Beat consensus by 33.2%, EPS $-0.05 vs $-0.0748 estimate
- mediumEarnings below estimates
Q4-2026: Missed consensus by 7.7%, EPS $-0.07 vs $-0.065 estimate
- high13F: large increase
CITADEL ADVISORS LLC added +949% to IBIO (2026Q2)
FREE, NO ACCOUNT
Every event on IBIO, as it fires
You are seeing 5 of 11 events recorded on IBIO since 2026-05-26.
The five above landed across 5 days. The other 6 were recorded on 3 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
IBIO positions held by the managers we follow (2026Q3)
What the managers we follow bought and sold in Q3 2026
| Manager / security | Market value | % of reported value |
|---|---|---|
| MILLENNIUM MANAGEMENT LLC FundCUSIP 451033708 · 2026Q3 | $1.7M | 0.00% |
| RENAISSANCE TECHNOLOGIES LLC FundCUSIP 451033708 · 2026Q3 | $812K | 0.00% |
| CITADEL ADVISORS LLC FundCUSIP 451033708 · 2026Q3 | $786K | 0.00% |
| TWO SIGMA INVESTMENTS, LP FundCUSIP 451033708 · 2026Q3 | $284K | 0.00% |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, IBIO
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
More data on IBIO
IBIO against its peers
IBIO's operating margin of -35141.0% ranks in the 4th percentile of 11 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.
| Metric | IBIO | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 100000 USD | 7.9M USD | 19 | 12 |
| Operating margin | -35141.0% | -111.0% | 4 | 11 |
| Net margin | -33044.0% | -80.1% | 13 | 11 |
| Return on equity | -38.6% | -72.3% | 66 | 15 |
| 1 year | -31.4% | -38.4% | 50 | 18 |
Peers (20): GANX, HOWL, ELOX, RNXT, AURX, IBO, VRCA, INKT, GNTA, XLO, BOLD, SGMOQ, FBIO, SPRO, ONCY, HRTX, MREO, XBIT, IMA, CGTX. Left out: APLM (period gap), HYFT (period gap), TNXP (no annual filing), ATHE (period gap), OKYO (period gap). Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (IBIO: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Cite this data
Kresmion counts the managers it follows that reported a non-option position in IBIO on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on IBIO in the last 180 days.
Upstream: SEC EDGAR filings for IBIO
Kresmion, "iBio, Inc. (IBIO) institutional holdings and SEC filings", data as of 2026-11-18, https://kresmion.com/research/IBIO. Upstream data: SEC EDGAR filings for IBIO.
Link to this data (HTML):
<a href="https://kresmion.com/research/IBIO">iBio, Inc. (IBIO) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow IBIO on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to IBIO for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.